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We thank Drs. Delimar, Smoljanovic, and Bojanic for their
interest in our article [1]. We share their concern that the
information about the clinical use of bone morphogenic
proteins (BMPs) should be thorough, clear, and state of the
art. Our review deals with various aspects of BMP use in
general fracture healing. We attempted to project new
developments and knowledge from basic science into
clinical situations. Where possible, we referred to previous
and more extensive papers in order to provide a general
overview of the use and efficacy of BMP treatment. We are
aware that this format did not allow us to thoroughly cover
all areas equally. With respect to the adverse effects of
BMPs, we consider the suggested literature by Delimar et
al., such as the recent review of BMP-2 treatment for spinal
surgery, as valuable additional and more specific informa-
tion to our paper [2]. We do appreciate the potential dangers
of bias by industry-sponsored publications [3], but we have
no connections whatsoever with the industry regarding this
matter. This is emphasised by the unbiased conclusion of
our paper, which states that the BMPs currently used to
enhance bone fracture healing are suboptimal, expensive,
and cause significant side effects. The take-home message
is that optimisation of BMPs is still required if these
compounds are to have widespread use in patients to
improve fracture healing. Moreover, we agree that most
bone fractures can be cared for using correct treatment
indications without the necessity of using BMPs. However,
for the 5–30% of fractures that will not heal after
nine months, BMPs or BMP-associated products could,
indeed, be useful. Therefore, we think that the answer to the
question: “Could the use of bone morphogenetic proteins in
fracture healing do more harm than good to our patients”?
depends on future research results and subsequent quality
and properties of specific BMPs, combined with specifica-
tions of patients and fractures.
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